A randomised study evaluating the use of pyridoxine to avoid capecitabine dose modifications.

Authors
Corrie, P
Bulusu, R
Wilson, C
Armstrong, G
Bond, S
Hardy, R
Lao-Sirieix, S
Parashar, D
Ahmad, A
Daniel, F
Hill, M
Wilson, Gregory
Blesing, C
Moody, A
McAdam, K
Osborne, M
Affiliation
Oncology Division, Addenbrooke's Hospital, Hills Road, Cambridge CB2 0QQ, UK.
Issue Date
2012-08-07

Metadata
Show full item record
Abstract
Pyridoxine is frequently used to treat capecitabine-induced hand-foot syndrome (HFS), although the evidence of benefit is lacking. We performed a randomised placebo-controlled trial to determine whether pyridoxine could avoid the need for capecitabine dose modifications and improve outcomes.
Citation
A randomised study evaluating the use of pyridoxine to avoid capecitabine dose modifications. 2012, 107 (4):585-7 Br J Cancer
Journal
British Journal of Cancer
URI
http://hdl.handle.net/10541/254625
DOI
10.1038/bjc.2012.318
PubMed ID
22814578
Type
Article
Language
en
ISSN
1532-1827
Collections